Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Orexigen Offers Robust Contrave Risk Plan To Monitor For Safety Concerns

Dec 13 2010

• By Cathy Dombrowski

Related Content

Panel Continues To Push For Obesity CV Guidance As It Backs <i>Contrave</i> Approval

Dec 13 2010

Qnexa May Get Staged Launch After No Vote From Advisory Panel

Jul 19 2010

REMS For Obesity Drugs May Need More Specifics After Qnexa Advisory Panel

Jul 19 2010

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window